This section includes links to information on the safety of Meningitis C vaccine, d/DTaP-IPV vaccines and general sources of information on vaccines.

The safety of Meningitis C vaccine

CSM review of the safety of Meningitis C vaccine (May 2002)PDF file (opens in new window) (42Kb)

Vaccinations against Meningitis C vaccine were introduced in the UK in November 1999 and over the subsequent 16 months virtually the whole population under the age of 18 was immunised. This paper reports on the work of a group that oversaw safety monitoring during this immunisation campaign. The CSM endorsed the general safety of Meningitis C vaccines.


d/DTaP (diphtheria, tetanus and pertussis)-IPV (inactivated polio vaccine) vaccines - local reactions associated with pre-school boosters
A review of the UK Yellow Card data indicates that booster doses of vaccines that contain acellular rather than wholecell pertussis in DTP vaccines (for example, Repevax, Infanrix-Hib) are associated with an increased risk of injection site reactions, some of which may be extensive.  Such reactions usually develop within 24 hours of vaccination but recover within five days.

Local reactions associated with pre-school d/DTaP-IPV boostersPDF file (opens in new window) (36Kb)  
 

General sources of vaccine information

NHS - Immunisation

Department of Health
'The Green Book' ('Immunisation Against Infectious Disease 1996')
'The Yellow Book' ('Health Information for overseas travel')

The Joint Committee on Vaccination and Immunisation (JCVI)

Health Protection Agency

World Health Organisation
 Vaccines and Immunisation
WHO vaccine safety index
WHO Global Advisory Committee on Vaccine Safety (GACVS)

United States Centres for Disease Control and Prevention (CDC)
CDC vaccine safety site

United States Food and Drug Administration (FDA) Center for Biologicals Evaluation and Research (CBER)

The US Institute of Medicine (IOM) - Immunisation Safety Review Committee


Page last modified: 30 September 2008